Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer TrialPRNewsWire • 03/31/22
Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing CohortPRNewsWire • 03/24/22
Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer ActivityPRNewsWire • 03/17/22
Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual MeetingPRNewsWire • 03/09/22
Oncolytics Biotech® Announces Upcoming Poster Presentation at the AACR Annual MeetingPRNewsWire • 03/09/22
Oncolytics Biotech, Inc. (ONCY) CEO Matthew Coffey on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/04/22
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational HighlightsPRNewsWire • 03/03/22
Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer TrialPRNewsWire • 02/02/22
Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast CancerPRNewsWire • 01/27/22
Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers SymposiumPRNewsWire • 01/20/22
Oncolytics Biotech® Releases a Letter to Shareholders - 2021 Review and 2022 OutlookPRNewsWire • 01/11/22
Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the Synergistic Anti-Leukemic Effects of Pelareorep Combined with Azacitidine at the 2021 American Society of Hematology Annual MeetingPRNewsWire • 12/15/21
Oncolytics Biotech® Presents Positive Interim Safety Update from Phase 2 Triple-Negative Breast Cancer Trial at the 2021 San Antonio Breast Cancer SymposiumPRNewsWire • 12/10/21
Oncolytics Biotech (ONCY) Sees Hammer Chart Pattern: Time to Buy?Zacks Investment Research • 12/03/21
Here's Why Oncolytics Biotech Inc. (ONCY) Could be Great Choice for a Bottom FisherZacks Investment Research • 12/01/21
Down 23.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Oncolytics Biotech Inc. (ONCY)Zacks Investment Research • 11/19/21
Oncolytics Biotech® to Present Phase 2 Triple-Negative Breast Cancer Trial Update at the 2021 San Antonio Breast Cancer SymposiumPRNewsWire • 11/19/21
Oncolytics Biotech Inc. (ONCY) CEO Matt Coffey on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/05/21
Oncolytics Biotech® Reports 2021 Third Quarter Development Highlights and Financial ResultsPRNewsWire • 11/05/21
Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal CancersPRNewsWire • 11/03/21
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational HighlightsPRNewsWire • 10/19/21
Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast CancerPRNewsWire • 10/14/21